Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
1(17%)
Results Posted
150%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
1
17%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

completed233%
recruiting117%
not_yet_recruiting117%
terminated233%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_1

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT04950764
recruitingphase_3

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617
not_yet_recruitingphase_2

Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).

NCT07305363
terminatedphase_2

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

NCT04024813
terminatedphase_2

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03551522
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04950764Phase 1

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Completed
NCT06051617Phase 3

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Recruiting
NCT07305363Phase 2

Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).

Not Yet Recruiting
NCT04024813Phase 2

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

Terminated
NCT03551522Phase 2

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Terminated
NCT03369002Phase 1

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6